Drug intelligence / Profile preview

walnut extract

Development stage: Unknown
Lead developer: Iveriapharma
Administration: Topical, Oral

Overview

Walnut extract is a natural agent derived from plant foods, categorized as a nutraceutical. It has been investigated for its therapeutic potential in various conditions. As an ingredient in Lazolex® Gel, it has been studied for its efficacy as an emollient gel in the treatment of mucocutaneous herpes simplex infections. Additionally, walnut extract has demonstrated renoprotective effects in preclinical models of chronic renal failure, where it improved renal function, oxidative stress, antioxidant, and inflammatory biomarkers. Liquisolid technology has been explored to enhance its solubility and absorption for improved renoprotective efficacy.

Other names: walnut extractEnglish walnut extractPersian walnut extract

Targets

AcetylcholinesteraseSYVN1 (E3 ubiquitin-protein ligase synoviolin)

Beyond the preview

Go deeper on walnut extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on walnut extract.

Explore the full profile